Does serum CA-125 level prior to second-look laparotomy for invasive ovarian adenocarcinoma predict size of residual disease?
1990; Elsevier BV; Volume: 38; Issue: 3 Linguagem: Inglês
10.1016/0090-8258(90)90076-w
ISSN1095-6859
AutoresBruce Patsner, James W. Orr, William J. Mann, Peyton T. Taylor, Edward E. Partridge, Tara Allmen,
Tópico(s)Urinary and Genital Oncology Studies
ResumoThe records of 125 patients with nonmucinous invasive ovarian adenocarcinoma who underwent cytoreductive surgery, cisplatin-based combination chemotherapy, and second-look laparotomy were analyzed to correlate pre-second-look serum CA-125 levels with the size of residual ovarian cancer. The majority of patients with negative second-look laparotomy had normal serum CA-125 levels (46/50 or 92%). Of the 75 patients with positive second-look, 56 (75%) had normal CA-125 levels preoperatively. Twenty-three of twenty-four (96%) patients with residual disease less than or equal to 1 cm had normal CA-125 levels as did 20 of 28 (71%) patients with disease 1.1-2.0 cm. Although elevated serum CA-125 levels were invariably associated with visible/gross disease and increasing size of residual disease tended to be associated with increasing elevations of CA-125, normal CA-125 levels often occurred in the presence of large-volume (greater than 2 cm) disease (13/23, 57%). The considerable overlap of serum CA-125 levels for all sizes of residual disease precluded precise prediction of residual disease size based on serum CA-125 level alone.
Referência(s)